Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.

Neuro-oncology - 14 Feb 2019

Sa Jason K, Kim Sung Heon, Lee Jin-Ku, Cho Hee Jin, Shin Yong Jae, Shin Hyemi, Koo Harim, Kim Donggeon, Lee Mijeong, Kang Wonyoung, Hong Sung Hee, Kim Jung Yong, Park Young-Whan, Song Seong-Won, Lee Song-Jae, Joo Kyeung Min, Nam Do-Hyun

Abstract excerpt

BACKGROUND: Cancer is a complex disease with profound genomic alterations and extensive heterogeneity. Recent studies on large-scale genomics have shed light on the impact of core oncogenic pathways, which are frequently dysregulated in a wide spectrum of cancer types. Aberrant activation of the hepatocyte growth factor (HGF) signaling axis has been associated with promoting various oncogenic programs during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cell Movement

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Hepatocyte Growth Factor

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Transcriptome

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29939324
DOI: 10.1093/neuonc/noy105
PMCID: PMC6374764

Genes

HGF
MET
GSC
KDR
SOX3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.PMID 29939324Read ↗

Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future DirectionsSemantic proximity Read ↗

HGF/MET Signaling in Malignant Brain TumorsSemantic proximity Read ↗

Targeting the hepatocyte growth factor/Met pathway in cancer.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Extensive MET alterations confer clinical response to MET inhibitors in gliomasSemantic proximity Read ↗

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastomaSemantic proximity Read ↗

Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cellsSemantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-METSemantic proximity Read ↗

High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.Semantic proximity Read ↗

Targeting the hedgehog pathway in MET mutation cancers and its effects on cells associated with cancer development.Semantic proximity Read ↗

Glioportal: a comprehensive transcriptomic resource unveiling ligand-mediated mesenchymal transition in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.